article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy.

Protein 263
article thumbnail

Researchers find that new approach to boosting protein production could advance mRNA and protein-based medicines

Medical Xpress

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Moderna reports ‘encouraging’ early data for one of its rare disease medicines

Bio Pharma Dive

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 294
article thumbnail

Key Parkinson’s protein could offer new potential targets for treatment

Pharma Times

Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. However, its relation to dopaminergic neuron death is unclear.

Protein 93
article thumbnail

Immunotherapy partnership advances space medicine research

Drug Discovery World

US company Vaxxinity and the University of Central Florida (UCF) have announced plans to work together to advance space medicine research. The research, funded by a grant from the State of Florida, aims to develop Vaxxinity’s active immunotherapies to prevent and mitigate muscle and bone wasting.

article thumbnail

Novartis buys Arvinas’ prostate cancer protein degrader for $150m

Drug Discovery World

Arvinas’ AR-V7-targeting PROTAC protein degrader is designed to target both AR-V7 and full-length AR. We are thrilled to partner with an organisation that shares our dedication to delivering transformative medicines to patients with significant unmet need,” said John Houston, Chairperson, President and Chief Executive Officer of Arvinas. “We

Protein 52
article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328